Racial Disparities Prevalent in Breast Cancer Recurrence Score and Mortality

Among patients with estrogen receptor (ER)-positive breast cancer, Black women are more likely to have a high-risk recurrence score, and those with axillary node–negative tumors have increased breast cancer–specific mortality within each risk category, according to a study now published in JAMA Oncology. In addition, the 21-gene Oncotype DX Breast Recurrence Score has less prognostic value for Black women. "The most commonly ordered genomic assay for obtaining prognostic information on the risk ...

Breast Cancer Survivors Face Increased Cardiovascular Risks

Compared with those without cancer, older patients with breast cancer have a higher risk of developing cardiovascular disease, according to a study now published in the Journal of the National Comprehensive Cancer Network. "In older women diagnosed with breast cancer, there is now a greater likelihood of dying of diseases other than the cancer itself," write the investigators, led by first author Anthony Matthews, PhD, a postdoctoral researcher at the Karolinska Institute in Sweden. "Cardiovascu...

Margetuximab Plus Chemo Approved for HER2-Positive Breast Cancer

The FDA has now approved margetuximab-cmkb (MargenzaTM, MacroGenics) in combination with chemotherapy for adult patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least two prior anti-HER2 regimens. "HER2-targeting monoclonal antibodies are the standard of care in early-to-advanced HER2-positive breast cancer," write the authors of the phase 3 SOPHIA trial on which the approval was based, led by Hope S. Rugo, MD, Director of...

Elevated Circulating Tumor DNA Associated With Lower Disease-Free Survival in Breast Cancer

In a meta-analysis now published in JAMA Network Open, elevated plasma circulating tumor DNA (ctDNA) was linked to an increased risk of relapse in patients with metastatic and locally advanced breast cancer, suggesting that ctDNA detection may help determine response to treatment and increase the possibility of early detection of progression and recurrence. "Circulating tumor DNA is a subgroup of cell-free DNA that is present in healthy individuals and is released from nonmalignant cells, and it...

Triple-Negative Breast Cancer: Which is Better, Adjuvant Chemotherapy or Radiotherapy?

In patients who have been diagnosed with T1 N0 M0 triple-negative breast cancer (TNBC), age plays a role in whether chemotherapy or radiotherapy will lead to better outcomes for overall survival and breast cancer–specific survival (BCSS), according to the results of a cohort study now published in JAMA Network Open. The investigators, led by Zhen Zhai, MD, of the Department of Breast Surgery in the First Affiliated Hospital in the College of Medicine at Zhejiang University in Hangzhou, China, en...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts